BioSpace News Archive

9 Meters Biopharma, Inc. today announced a collaboration agreement with Gustave Roussy, a leading cancer center in Villejuif, France, using 9 Meters’ small molecule tight junction microbiome modulator NM-102.

Surmodics, Inc. today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022.

Pyxis Oncology, Inc., announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.

Hepion Pharmaceuticals, Inc. today announced that results from a study conducted by Dr. Philippe Gallay’s research group at The Scripps Research Institute examining the anti-tumor mechanism of the Company’s lead drug candidate, CRV431, will be available as an e-poster at the Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held virtually November 12-15, 2021.

Vaccinex, Inc. (Nasdaq: VCNX), today announced that Dr. Elizabeth Evans, PhD, Chief Operating Officer and SVP, Discovery and Translational Medicine, will present Poster #434, Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84), at the Society for Immunology of Cancer’s (SITC) 36th Annual Meeting.

SOPHiA GENETICS SA, reported financial results for the third quarter ended September 30, 2021.

Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, published positive preclinical data in non-human primate models from the CORAL next-generation COVID-19 vaccine program against SARS-CoV-2, the coronavirus that causes COVID-19 disease.

Yumanity Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease.

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in-person at the 12th Annual Jefferies London Healthcare Conference on November 17, 2021, at 1:00pm GMT.

Diffusion Pharmaceuticals Inc., a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced financial results for the third quarter of 2021 and provided a business update.